Chidamide plus R‐GDP for relapsed/refractory diffuse large B‐cell lymphoma in patients ineligible for autologous transplantation: A prospective, single‐arm, phase II study

Chidamide plus R‐GDP for relapsed/refractory diffuse large B‐cell lymphoma in patients ineligible for autologous transplantation: A prospective, single‐arm, phase II study

Abstract Background In relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL), a negative prognosis is frequently linked to heightened epigenetic heterogeneity. Chidamide, a selective histone deacetylase inhibitor, shows promise as a targeted therapy for R/R DLBCL by targeting abnormal epig...

Full description

Saved in:
Bibliographic Details
Main Authors: Guang‐Liang Chen, Kai Xue, Qunling Zhang, Zu‐guang Xia, Jia Jin, Ran Li, Yizhen Liu, Fangfang Lv, Xiaonan Hong, Xiaoqiu Li, Junning Cao
Format: Article
Language:English
Published: Wiley 2024-08-01
Series:Cancer Medicine
Subjects:
autologous transplantation
chidamide
clinical trial
diffuse large B‐cell lymphoma
epigenetic mechanisms
relapsed/refractory
Online Access:https://doi.org/10.1002/cam4.70142
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.70142

Similar Items